

A Novel Approach for the Synthesis of 5-Substituted-1H-tetrazoles

Batool Akhlaghinia* and Soodabeh Rezazadeh

Department of Chemistry, Faculty of Sciences, Ferdowsi University of Mashhad, 9177948974 Mashhad, Iran

Experimental

General

The products were purified by column chromatography. The purity determinations of the products were accomplished by TLC on silica gel polygram STL G/UV 254 plates. The melting points of products were determined with an Electrothermal Type 9100 melting point apparatus. The FT-IR spectra were recorded on an Avatar 370 FT-IR Therma Nicolet spectrometer. The NMR spectra were provided on a Brucker Avance 100 and 400 MHz instrument in DMSO. All of the products were known compounds and characterized by the IR, ¹H NMR and ¹³C NMR spectra and comparison of their melting points with known compounds. Elemental analyses were performed using a Elementar, Vario EL III and Thermofinnigan Flash EA 1112 Series instrument. Mass spectra were recorded with Shimadzu GC-MS-QP5050A and Aglien Technology (HP) 5973 Network Mass Selective Detector instruments at 70 eV; in m/z (rel %).



Figure S1. ¹H NMR (400 MHz, DMSO-*d*₆) of 5-phenyl-1*H*-tetrazole (1).

*e-mail: akhlaghinia@um.ac.ir



Figure S2. ¹³C NMR (100 MHz, DMSO- d_6) of 5-phenyl-1*H*-tetrazole (1).



Figure S3. ¹³C NMR (100 MHz, DMSO-*d*₆) of 5-phenyl-1*H*-tetrazole (1) expanded.



Figure S4. FT-IR (KBr) of 5-phenyl-1*H*-tetrazole (1).



Figure S5. ¹H NMR (100 MHz, DMSO- d_6) of 5-(4-bromophenyl)-1*H*-tetrazole (2).



Figure S6. FT-IR (KBr) of 5-(4-bromophenyl)-1*H*-tetrazole (2).



Figure S7. Mass spectrum of 5-(4-bromophenyl)-1*H*-tetrazole (2).



Figure S8. ¹H NMR (400 MHz, DMSO-*d*₆) of 5-(4-chlorophenyl)-1*H*-tetrazole (3).



Figure S9. ¹³C NMR (100 MHz, DMSO- d_6) of 5-(4-chlorophenyl)-1*H*-tetrazole (3).



Figure S10. FT-IR (KBr) of 5-(4-chlorophenyl)-1*H*-tetrazole (3).



Figure S11. ¹H NMR (100 MHz, CD₃CN) of 4-(1*H*-tetrazol-5-yl)benzonitrile (4).



Figure S12. FT-IR (KBr) of 4-(1*H*-tetrazol-5-yl)benzonitrile (4).



Figure S13. ¹H NMR (400 MHz, DMSO-*d*₆) of 5-(4-nitrophenyl)-1*H*-tetrazole (5).



Figure S14. ¹H NMR (400 MHz, DMSO-*d*₆) of 5-(4-nitrophenyl)-1*H*-tetrazole (5) expanded.



Figure S15. ¹³C NMR (100 MHz, DMSO- d_6) of 5-(4-nitrophenyl)-1*H*-tetrazole (5).



Figure S16. FT-IR (KBr) of 5-(4-nitrophenyl)-1*H*-tetrazole (5).



Figure S17. ¹H NMR (400 MHz, DMSO-*d*₆) of 4-nitro-2-(1*H*-tetrazol-5-yl)benzenamine (6).



Figure S18. ¹H NMR (400 MHz, DMSO-*d*₆) of 4-nitro-2-(1*H*-tetrazol-5-yl)benzenamine (6) expanded.



Figure S19. ¹³C NMR (100 MHz, DMSO-*d*₆) of 4-nitro-2-(1*H*-tetrazol-5-yl)benzenamine (6).





Figure S20. ¹³C NMR (100 MHz, DMSO-*d*₆) of 4-nitro-2-(1*H*-tetrazol-5-yl)benzenamine (6) expanded.



Figure S21. FT-IR (KBr) of 4-nitro-2-(1*H*-tetrazol-5-yl)benzenamine (6).



Figure S22. ¹H NMR (100 MHz, acetone- d_6) of 5-(4-ethoxyphenyl)-1*H*-tetrazole (7).



Figure S23. FT-IR (KBr) of 5-(4-ethoxyphenyl)-1*H*-tetrazole (7).



Figure S24. ¹H NMR (400 MHz, DMSO- d_{δ}) of 5-(3,5-dimethoxyphenyl)-1*H*-tetrazole (8).



Figure S25. 13 C NMR (100 MHz, DMSO- d_6) of 5-(3,5-dimethoxyphenyl)-1*H*-tetrazole (8).



Figure S26. FT-IR (KBr) of 5-(3,5-dimethoxyphenyl)-1*H*-tetrazole (8).



Figure S27. Mass spectrum of 5-(3,5-dimethoxyphenyl)-1*H*-tetrazole (8).



Figure S28. ¹H NMR (100 MHz, CD₃CN) of 5-*m*-tolyl-1*H*-tetrazole (9).



Figure S29. FT-IR (KBr) of 5-*m*-tolyl-1*H*-tetrazole (9).



Figure S30. ¹H NMR (400 MHz, DMSO-*d*₆) of 4-(1*H*-tetrazol-5-yl) phenol (**10**).



Figure S31. ¹H NMR (400 MHz, DMSO-*d*₆) of 4-(1*H*-tetrazol-5-yl)phenol (10) expanded.



Figure S32. ¹³C NMR (100 MHz, DMSO- d_6) of 4-(1*H*-tetrazol-5-yl) phenol (10).



Figure S33. FT-IR (KBr) of 4-(1*H*-tetrazol-5-yl) phenol (10).



Figure S34. ¹H NMR (100 MHz, DMSO-*d*₆) of 5-(phenanthren-9-yl)-1*H*-tetrazole (11).



Figure S35. FT-IR (KBr) of 5-(phenanthren-9-yl)-1*H*-tetrazole (11).



Figure S36. Mass spectrum of 5-(phenanthren-9-yl)-1*H*-tetrazole (11).



Figure S37. ¹H NMR (100 MHz, CD₃CN) of 5-(thiophen-2-yl)-1*H*-tetrazole (12).



Figure S38. FT-IR (KBr) of 5-(thiophen-2-yl)-1*H*-tetrazole (12).



Figure S39. Mass spectrum of 5-(thiophen-2-yl)-1*H*-tetrazole (12).



Figure S40. FT-IR (KBr) of 4-(1*H*-tetrazol-5-yl) pyridine (13).



Figure S41. ¹H NMR (400 MHz, DMSO- d_{δ}) of 2-(1*H*-tetrazol-5-yl)pyridine (14).



Figure S42. ¹³C NMR (100 MHz, DMSO-*d*₆) of 2-(1*H*-tetrazol-5-yl) pyridine (**14**).



Figure S43. FT-IR of 2-(1*H*-tetrazol-5-yl) pyridine (14).



Figure S44. FT-IR of 5-isobutyl-1*H*-tetrazole (15).



Figure S45. ¹H NMR (100 MHz, CDCl₃) of 5-isopentyl-1*H*-tetrazole (16).



Figure S46. FT-IR of 5-isopentyl-1*H*-tetrazole (16).



Figure S47. ¹H NMR (100 MHz, CD₃CN) of 5-benzyl-1*H*-tetrazole (17).



Figure S48. FT-IR of 5-benzyl-1*H*-tetrazole (17).